©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jun 26, 2025; 17(6): 108197
Published online Jun 26, 2025. doi: 10.4252/wjsc.v17.i6.108197
Published online Jun 26, 2025. doi: 10.4252/wjsc.v17.i6.108197
Mesenchymal stem cell-derived extracellular vesicles: Pioneering the next generation of biomedical applications
Tong-Ming Liu, Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Singapore 138648, Singapore
Author contributions: Liu TM contributed to conceptualization, manuscript writing, and revision; The author read and agreed to the published version of the manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Tong-Ming Liu, PhD, Senior Scientist, Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, No. 61 Biopolis Drive, Proteos, Singapore 138673, Singapore. dbsliutm@yahoo.com
Received: April 8, 2025
Revised: April 25, 2025
Accepted: June 6, 2025
Published online: June 26, 2025
Processing time: 79 Days and 3.5 Hours
Revised: April 25, 2025
Accepted: June 6, 2025
Published online: June 26, 2025
Processing time: 79 Days and 3.5 Hours
Core Tip
Core Tip: Mesenchymal stem cell (MSC)-derived extracellular vesicles (MSC-EVs) are cell-free nanoparticles that offer several advantages over MSCs, including greater stability and lower immunogenicity. These vesicles have shown significant potential in the treatment of various diseases. This article explored the applications of MSC-EVs in hair regeneration, immunomodulation, and the treatment of acute kidney injury. It also highlighted the challenges associated with MSC-EV-based therapies, underscoring the need for continued research and innovation to address these obstacles and advance MSC-EV development and clinical translation.